1. Menéndez-Arias, L.; Delgado, R. Update and latest advances in antiretroviral therapy. Trends Pharmacol. Sci. 2022, 43(1), 16–29. DOI: 10.1016/j.tips.2021.10.004
2. Peng, Y.; Zong, Y.; Wang, D.; Chen, J.; Chen, Z.S.; Peng, F.; Liu, Z. Current drugs for HIV-1: from challenges to potential in HIV/AIDS. Front. Pharmacol. 2023, 14, Art. No: 1294966. DOI: 10.3389/fphar.2023.1294966
3. Watkins, M.E.; Wring, S.; Randolph, R.; et al. Development of a novel formulation that improves preclinical bioavailability of tenofovir disoproxil fumarate. J. Pharm. Sci. 2017, 106, 906–919. DOI: 10.1016/j.xphs.2016.12.015
4. Sangeetha, S. Formulation Design, Optimization, and Evaluation of Solid Lipid Nanoparticles Loaded With an Antiviral Drug Tenofovir Using Box–Behnken Design for Boosting Oral Bioavailability. Adv. Pharmacol. Pharm. Sci. 2024, 2024, Art. No: 5248746. DOI: 10.1155/2024/5248746
5. Limenh, L.W. Advances in the transdermal delivery of antiretroviral drugs. SAGE Open Med. 2024, 12, Art. No: 20503121231223600. DOI: 10.1177/20503121231223600
6. Burns, R.N.; Hendrix, C.W.; Chaturvedula, A. Population pharmacokinetics of tenofovir and tenofovir‐diphosphate in healthy women. J. Clin. Pharmacol. 2015, 55, 629–638. DOI: 10.1002/jcph.464
7. Hagos, Y.; Wolff, N.A. Assessment of the role of renal organic anion transporters in drug-induced nephrotoxicity. Toxins 2010, 2, 2055–2082. DOI: 10.3390/toxins2082055
8. Kohler, J.J.; Hosseini, S.H.; Green, E.; et al. Tenofovir renal proximal tubular toxicity is regulated by OAT1 and MRP4 transporters. Lab. Invest. 2011, 91, 852–858. DOI: 10.1038/labinvest.2011.35
9. Agrahari, V.; Putty, S.; Mathes, C.; et al. Evaluation of degradation kinetics and physicochemical stability of tenofovir. Drug Test. Anal. 2015, 7, 207–213. DOI: 10.1002/dta.1659
10. De Clercq, E. Tenofovir alafenamide (TAF) as the successor of tenofovir disoproxil fumarate (TDF). Biochem. Pharmacol. 2016, 119, 1–7. DOI: 10.1016/j.bcp.2016.04.002
11. Murphy, R.A.; Valentovic, M.A. Factors contributing to the antiviral effectiveness of tenofovir. J. Pharmacol. Exp. Ther. 2017, 363, 156–163. DOI: 10.1124/jpet.117.242073
12. Singireddy, A.R.; Pedireddi, S.R. Advances in lopinavir formulations: strategies to overcome solubility, bioavailability, and stability challenges. Prospect. Pharm. Sci. 2024, 22, 105–121. DOI: 10.56782/pps.280
13. Cobb, D.A.; Smith, N.; Deodhar, S.; et al. Transformation of tenofovir into stable ProTide nanocrystals with long-acting pharmacokinetic profiles. Nat. Commun. 2021, 12, Art. No: 5458. DOI: 10.1038/s41467-021-25770-4
14. Safari, J.B.; Bapolisi, A.M.; Krause, R.W. Development of pH-sensitive chitosan-g-poly(acrylamide-co-acrylic acid) hydrogel for controlled drug delivery of tenofovir disoproxil fumarate. Polymers 2021, 13, Art. No: 3571. DOI: 10.3390/polym13203571
15. Zhang, T.; Zhang, C.; Agrahari, V.; et al. Spray drying tenofovir loaded mucoadhesive and pH-sensitive microspheres intended for HIV prevention. Antivir. Res. 2013, 97, 334–346. DOI: 10.1016/j.antiviral.2012.12.008
16. Pribut, N.; D’Erasmo, M.; Dasari, M.; et al. ω-Functionalized lipid prodrugs of HIV NtRTI tenofovir with enhanced pharmacokinetic properties. J. Med. Chem. 2021, 64, 12917–12937. DOI: 10.1021/acs.jmedchem.1c00928
17. Reddy, D.M.; Chetty, C.M.; Reddy, Y.D.; et al. Formulation and Evaluation of fast dissolving buccal patches of tenofovir disoproxil fumarate. Res. J. Pharm. Technol. 2021, 14, 225–230. DOI: 10.52711/0974-360X.2021.00038
18. Cazorla-Luna, R.; Notario-Pérez, F.; Martín-Illana, A.; et al. Chitosan-based mucoadhesive vaginal tablets for controlled release of the anti-HIV drug tenofovir. Pharmaceutics 2019, 11, Art. No: 20. DOI: 10.3390/pharmaceutics11010020
19. Belletti, D.; Tosi, G.; Forni, F.; et al. Chemico-physical investigation of tenofovir loaded polymeric nanoparticles. Int. J. Pharm. 2012, 436, 753–763. DOI: 10.1016/j.ijpharm.2012.06.059
20. Mathieu, T.; Favetta, P.; Agrofoglio, L.A. Molecularly Imprinted Polymeric Nanoparticles as Drug Delivery System for Tenofovir, an Acyclic Nucleoside Phosphonate Antiviral. Pharmaceutics 2024, 16, Art. No: 965. DOI: 10.3390/pharmaceutics16070965
21. Zidan, A.S.; Spinks, C.B.; Habib, M.J.; et al. Formulation and transport properties of tenofovir loaded liposomes through Caco-2 cell model. J. Liposome Res. 2013, 23, 318–326. DOI: 10.3109/08982104.2013.814823
22. Spinks, C.B.; Zidan, A.S.; Khan, M.A.; et al. Pharmaceutical characterization of novel tenofovir liposomal formulations for enhanced oral drug delivery: in vitro pharmaceutics and Caco-2 permeability investigations. Clin. Pharmacol. Adv. Appl. 2017, 9, 29–38. DOI: 10.2147/CPAA.S122449
23. Khatoon, M.; Shah, K.U.; Din, F.U.; et al. Proniosomes derived niosomes: recent advancements in drug delivery and targeting. Drug Deliv. 2017, 24, 56–69. DOI: 10.1080/10717544.2016.1230054
24. Khindri, S.; Aggarwal, G.; Hari Kumar, S.L. Role of niosomes and proniosomes for enhancing bioavailability of drugs. J. Drug Deliv. Ther. 2015, 5, 28–33. DOI: 10.22270/jddt.v5i1.1004
25. Song, S.; Tian, B.; Chen, F.; et al. Potentials of proniosomes for improving the oral bioavailability of poorly water-soluble drugs. Drug Dev. Ind. Pharm. 2015, 41, 51–62. DOI: 10.3109/03639045.2013.865234
26. Ahmed, S.; Farag, M.M.; Attia, H.; et al. Exploring the potential of antifungal-loaded proniosomes to consolidate corneal permeation in fungal keratitis: A comprehensive investigation from laboratory characterization to microbiological evaluation. Int. J. Pharm. X 2025, 9, Art. No: 100322. DOI: 10.1016/j.ijpx.2024.100322
27. Thongpon, P.; Intuyod, K.; Pongking, T.; et al. Curcumin-Loaded Maltodextrin-Based Proniosomes Potentially Effective against Gemcitabine-Resistant Cholangiocarcinoma. ACS Appl. Bio Mater. 2025, 8, 913-930. DOI: 10.1021/acsabm.4c01832
28. Anwer, K.E.; El-Sattar, N.E.; Shamaa, M.M.; et al. Design, green synthesis and tailoring of vitamin E TPGS augmented niosomal nano-carrier of pyrazolopyrimidines as potential anti-liver and breast cancer agents with accentuated oral bioavailability. Pharmaceuticals 2022, 15, Art. No: 330. DOI: 10.3390/ph15030330
29. Paarakh, M.P.; Jose, P.A.; Setty, C.M.; Peterchristoper, G.V. Release kinetics–concepts and applications. Int. J. Pharm. Res. Technol. 2018, 8, 12–20.
30. Askarizadeh, M.; Esfandiari, N.; Honarvar, B.; et al. Kinetic modeling to explain the release of medicine from drug delivery systems. ChemBioEng Rev. 2023, 10, 1006–1049. DOI: 10.1002/cben.202300065
31. Atnip, A.; Giusti, M.M.; Sigurdson, G.T.; et al. The NCI-N87 cell line as a gastric epithelial model to study cellular uptake, trans-epithelial transport, and gastric anti-inflammatory properties of anthocyanins. Nutr. Cancer 2020, 72, 686–695. DOI: 10.1080/01635581. 2019.1655646
32. Gharbavi, M.; Johari, B.; Mousazadeh, N.; et al. Hybrid of niosomes and bio-synthesized selenium nanoparticles as a novel approach in drug delivery for cancer treatment. Mol. Biol. Rep. 2020, 47, 6517–6529. DOI: 10.1007/s11033-020-05683-7
33. Singireddy, A.; Pedireddi, S.R.; Subramanian, S. Optimization of reaction parameters for synthesis of Cyclodextrin nanosponges in controlled nanoscopic size dimensions. J. Polym. Res. 2019, 26, Art. No: 93. DOI: 10.1007/s10965-019-1743-3